Phase 2 Eczema Trial, Recruiting (NCT07223697)

Phase 2 Eczema Trial, Recruiting NCT07223697 Sponsor: Hoffmann-La Roche Condition: Eczema

Printed from Voxsanity (voxsanity.com.au) — NCT07223697 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Eczema

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are able and willing to follow all parts of the study, including completing skin and quality-of-life questionnaires and providing blood samples throughout the study period
People who were already taking part in a related study called CS45570, were still being assessed at the Week 36 follow-up visit, and whose skin condition improved by at least 50% (measured by a standard scoring system called EASI) compared to when that study began

Who may not be able to join:

People who have another skin condition that could make it difficult for doctors to accurately assess their eczema
People who withdrew their consent or left the earlier related study (CS45570) before it was completed
People whose study medication was permanently stopped at any point during the earlier related study
People who have had a severe allergic reaction or a life-threatening allergic reaction (called anaphylaxis) to any biologic medicine, or who are known to have a sensitivity to any ingredient in the study drug, Afimkibart

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 20 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Clinical Trials, Hoffmann-La Roche

Phone: 888-662-6728 (U.S. Only)

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07223697

Sponsor: Hoffmann-La Roche

Phase: Phase 2

Status: Recruiting

Condition: Eczema

Trial contact: 888-662-6728 (U.S. Only)

More information: https://clinicaltrials.gov/study/NCT07223697

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are able and willing to follow all parts of the study, including completing skin and quality-of-life questionnaires and providing blood samples throughout the study period
People who were already taking part in a related study called CS45570, were still being assessed at the Week 36 follow-up visit, and whose skin condition improved by at least 50% (measured by a standard scoring system called EASI) compared to when that study began

Who may not be able to join:

People who have another skin condition that could make it difficult for doctors to accurately assess their eczema
People who withdrew their consent or left the earlier related study (CS45570) before it was completed
People whose study medication was permanently stopped at any point during the earlier related study
People who have had a severe allergic reaction or a life-threatening allergic reaction (called anaphylaxis) to any biologic medicine, or who are known to have a sensitivity to any ingredient in the study drug, Afimkibart

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 20 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Hoffmann-La Roche

Registry

ClinicalTrials.gov

Start date

8 January 2026

Est. completion

1 March 2033

Where this trial is recruiting

🇧🇷 Brazil 🇨🇦 Canada 🇩🇪 Germany 🇵🇱 Poland 🇪🇸 Spain 🇺🇸 United States

Primary endpoints

Percentage of Participants with Adverse Events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov